The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?

Bibliographic Details
Title: The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
Authors: Anjali Bhatt, Kerrington Powell, Vinay Prasad
Source: Translational Oncology, Vol 25, Iss , Pp 101523- (2022)
Publisher Information: Elsevier, 2022.
Publication Year: 2022
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: AGILE, IDH1-mutant acute myeloid leukemia, Ivosidenib, Azacitidine, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: The AGILE trial compared ivosidenib and azacitidine versus azacitidine for IDH1-mutant acute myeloid leukemia (AML) in elderly patients who were ineligible to receive intensive chemotherapy. While the results of this trial appear encouraging, various concerns become evident from the study design and methodology. First, the AGILE trial did not use post-protocol therapy that met the current standard of care. Second, researchers continued patient enrollment despite knowledge of the survival benefit of azacitidine plus venetoclax shown in the VIALE-A trial, resulting in an inferior control arm. Third, the primary endpoint of AGILE was changed from overall survival (OS) to event-free survival (EFS), and the sample size was reduced to expedite the results. Finally, the trial was halted early based on a non-primary endpoint, which likely led to exaggerated effect size or misleading results. We discuss these limitations and continue to advocate for careful analysis of study design to ensure that appropriate and accurate outcomes are implemented in future studies.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1936-5233
Relation: http://www.sciencedirect.com/science/article/pii/S1936523322001826; https://doaj.org/toc/1936-5233
DOI: 10.1016/j.tranon.2022.101523
Access URL: https://doaj.org/article/65de1306450f494b813c045ecfec8c9e
Accession Number: edsdoj.65de1306450f494b813c045ecfec8c9e
Database: Directory of Open Access Journals
More Details
ISSN:19365233
DOI:10.1016/j.tranon.2022.101523
Published in:Translational Oncology
Language:English